Evidence on Effectiveness of Oral Contraceptive Use for Prevention of Ovarian Cancer Is Inconclusive, AHRQ-CDC Evidence Shows

Insufficient evidence exists to recommend for or against the use of oral contraceptives solely for the prevention of ovarian cancer, according to findings of a new review from AHRQ and CDC. Oral contraceptives may increase life expectancy by one month when other medical benefits are included (e.g., reduced deaths from ovarian, colorectal, and endometrial cancers). However, the harm/benefit ratio of oral contraceptives for ovarian cancer prevention alone is uncertain when factored in with the increased risk of breast cancer, cervical cancer, and cardiovascular events associated with their use. More well-designed research studies are needed to determine whether using oral contraceptives solely to prevent ovarian cancer can be recommended in light of the demonstrated risks. Select to access the research review, Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer.

Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer - Research Review - Final | AHRQ Effective Health Care Program